Exact Mass: 519.3613

Exact Mass Matches: 519.3613

Found 224 metabolites which its exact mass value is equals to given mass value 519.3613, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

2-linoleoyl-sn-glycero-3-phosphocholine

2-linoleoyl-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


   

1-linoleoyl-GPC (18:2)

(2-{[(2R)-2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H50NO7P (519.3325)


LysoPC(18:2(9Z,12Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:2(9Z,12Z)), in particular, consists of one chain of linoleic acid at the C-1 position. The linoleic acid moiety is derived from seed oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   

LysoPC(0:0/18:2(9Z,12Z))

(2-{[(2R)-3-hydroxy-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H50NO7P (519.3325)


LysoPC(0:0/18:2(9Z,12Z)) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/18:2(9Z,12Z)), in particular, consists of one chain of linoleic acid at the C-2 position.

   

(4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-Trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine

3-[(7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


(4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-Trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine

3-[(7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

3-({10-hydroxy-12-[5-hydroxy-3-oxo-2-(pent-2-en-1-yl)cyclopentyl]dodeca-4,7,11-trienoyl}oxy)-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

C29H45NO7 (519.3196)


(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-[(1S,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine

3-({3-[5-hydroxy-2-(3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl]propanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


3-[(1S,2R,5S)-5-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-[(1S,2R,5S)-5-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-[(1S,2R,5S)-5-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 3-[(1S,2R,5S)-5-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine

3-({3-[3-hydroxy-2-(3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl]propanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


3-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 3-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z)-6-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine

3-({6-[3-hydroxy-2-(3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl]hex-4-enoyl}oxy)-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


(4Z)-6-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-6-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-6-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z)-6-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z)-9-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine

3-({9-[3-hydroxy-2-(3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl]nona-4,7-dienoyl}oxy)-4-(trimethylazaniumyl)butanoate

C29H45NO7 (519.3196)


(4Z,7Z)-9-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z)-9-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z)-9-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z)-9-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z)-12-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine

3-({12-[3-hydroxy-2-(3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl]dodeca-4,7,10-trienoyl}oxy)-4-(trimethylazaniumyl)butanoic acid

C29H45NO7 (519.3196)


(4Z,7Z,10Z)-12-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z)-12-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z)-12-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z)-12-[(1S,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4S,5E)-4-Hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine

3-({4-hydroxy-6-[5-hydroxy-3-oxo-2-(undeca-2,5,8-trien-1-yl)cyclopentyl]hex-5-enoyl}oxy)-4-(trimethylazaniumyl)butanoic acid

C29H45NO7 (519.3196)


(4S,5E)-4-hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (4S,5E)-4-hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4S,5E)-4-hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4S,5E)-4-hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7S,8E)-7-Hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine

3-({7-hydroxy-9-[5-hydroxy-2-(octa-2,5-dien-1-yl)-3-oxocyclopentyl]nona-4,8-dienoyl}oxy)-4-(trimethylazaniumyl)butanoic acid

C29H45NO7 (519.3196)


(4Z,7S,8E)-7-hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7S,8E)-7-hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7S,8E)-7-hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7S,8E)-7-hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Boceprevir

3-{2-[N-tert-butyl-(C-hydroxycarbonimidoyl)amino]-3,3-dimethylbutanoyl}-N-(1-carbamoyl-3-cyclobutyl-1-oxopropan-2-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboximidate

C27H45N5O5 (519.3421)


   

Asi-222

3-[3-(5-amino-3,4-dihydroxy-6-methyloxan-2-yl)oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

C29H45NO7 (519.3196)


D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

   

Phosphatidylcholine lyso 18:2

Phosphatidylcholine lyso 18:2

C26H50NO7P (519.3325)


   
   
   

LPC(1-acyl 18:2)-2

LPC(1-acyl 18:2)-2

C26H50NO7P (519.3325)


   

1-Hydroxy-2-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-2-phosphocholine

1-Hydroxy-2-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-2-phosphocholine

C26H50NO7P (519.3325)


   

1-(9Z,12Z-Octadecadienoyl-2-hydroxy-sn-glycero-3-phosphocholine

1-(9Z,12Z-Octadecadienoyl-2-hydroxy-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


   

LPC 18:2

1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


Annotation level-3

   

LysoPC(18:2/0:0)

(2-{[(2R)-2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H50NO7P (519.3325)


   

1-Linoleoylglycerophosphocholine

2-[hydroxy-[2-hydroxy-3-[(9Z,12Z)-octadeca-9, 12-dienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C26H50NO7P (519.3325)


   

Phe Ile Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-3-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Phe Ile Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]hexanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Ile Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]hexanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Ile Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-4-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Phe Lys Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-methylpentanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Lys Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-methylpentanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Lys Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-4-methylpentanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Lys Leu Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-4-methylpentanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Leu Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-3-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Phe Leu Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]hexanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Leu Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]hexanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Phe Leu Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-4-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Phe Arg Val Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Phe Val Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Phe Val Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O5 (519.3169)


   

Ile Phe Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-3-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Ile Phe Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]hexanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Ile Phe Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]hexanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Ile Phe Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-4-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Ile Ile Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Ile Ile Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Ile Lys Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Ile Lys Phe Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Ile Lys Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Ile Lys Leu Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Ile Leu Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Ile Leu Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Lys Phe Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-3-methylpentanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Phe Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-3-methylpentanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Phe Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-4-methylpentanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Phe Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-4-methylpentanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Ile Phe Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Ile Phe Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Ile Ile Phe

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Lys Ile Leu Phe

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Lys Leu Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Leu Phe Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Lys Leu Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Lys Leu Leu Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Leu Phe Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-3-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Leu Phe Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]hexanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Leu Phe Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]hexanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Leu Phe Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-4-methylpentanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Leu Ile Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Leu Ile Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Leu Lys Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Leu Lys Phe Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C27H45N5O5 (519.3421)


   

Leu Lys Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Leu Lys Leu Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Leu Leu Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C27H45N5O5 (519.3421)


   

Leu Leu Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C27H45N5O5 (519.3421)


   

Arg Phe Val Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methylbutanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Arg Val Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Arg Val Val Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C25H41N7O5 (519.3169)


   

Val Phe Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Val Phe Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O5 (519.3169)


   

Val Arg Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C25H41N7O5 (519.3169)


   

Val Arg Val Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C25H41N7O5 (519.3169)


   

Val Val Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C25H41N7O5 (519.3169)


   

Val Val Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C25H41N7O5 (519.3169)


   

PC(18:2/0:0)

3,5,9-Trioxa-4-phosphaheptacosa-11,13-dien-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-

C26H50NO7P (519.3325)


   

18:2 LYSO-PC

3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, [R-(Z,Z)]-

C26H50NO7P (519.3325)


   

Linoleoyllysolecithin

1-mono-, 3-(dihydrogen phosphate), monoester with choline hydroxide, inner salt

C26H50NO7P (519.3325)


   

PC(P-19:1/0:0)

1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphocholine

C27H54NO6P (519.3689)


   

LPC O-19:2

1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphocholine

C27H54NO6P (519.3689)


   

Poly(1,2-dihydro-2,2,4-trimethylquinoline)

Poly(1,2-dihydro-2,2,4-trimethylquinoline)

C36H45N3 (519.3613)


   

Boc-d-dap(z)-oh dcha

Boc-d-dap(z)-oh dcha

C28H45N3O6 (519.3308)


   

BOCEPREVIR

BOCEPREVIR

C27H45N5O5 (519.3421)


J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections C254 - Anti-Infective Agent > C281 - Antiviral Agent COVID info from Guide to PHARMACOLOGY Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

N-Boc-N-Cbz-L-2,3-diaminopropionic acid dicyclohexylamine salt

N-Boc-N-Cbz-L-2,3-diaminopropionic acid dicyclohexylamine salt

C28H45N3O6 (519.3308)


   
   
   

1-linoleoyl-GPC (18:2)

(2-{[(2R)-2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H50NO7P (519.3325)


LysoPC(18:2(9Z,12Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:2(9Z,12Z)), in particular, consists of one chain of linoleic acid at the C-1 position. The linoleic acid moiety is derived from seed oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Lysopc(18:2(9z,12z)), also known as lysophosphatidylcholine(18:2/0:0) or lpc(18:2n6/0:0), is a member of the class of compounds known as 1-acyl-sn-glycero-3-phosphocholines. 1-acyl-sn-glycero-3-phosphocholines are glycerophosphocholines in which the glycerol is esterified with a fatty acid at O-1 position, and linked at position 3 to a phosphocholine. Thus, lysopc(18:2(9z,12z)) is considered to be a glycerophosphocholine lipid molecule. Lysopc(18:2(9z,12z)) is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Lysopc(18:2(9z,12z)) can be found in a number of food items such as japanese persimmon, jicama, rubus (blackberry, raspberry), and chinese bayberry, which makes lysopc(18:2(9z,12z)) a potential biomarker for the consumption of these food products. Lysopc(18:2(9z,12z)) can be found primarily in blood, feces, and urine, as well as throughout all human tissues. Moreover, lysopc(18:2(9z,12z)) is found to be associated with schizophrenia.

   

(2-Hydroxy-3-octadeca-9,12-dienoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(2-Hydroxy-3-octadeca-9,12-dienoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

(4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-Trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine

(4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-Trihydroxydocosa-4,8,10,12,14,19-hexaenoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-Trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine

(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-Trihydroxydocosa-4,9,11,13,15,19-hexaenoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

(4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine

C29H45NO7 (519.3196)


   

3-[(1S,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine

3-[(1S,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-3-oxocyclopentyl]propanoylcarnitine

C29H45NO7 (519.3196)


   

3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine

3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine

C29H45NO7 (519.3196)


   

(4Z)-6-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine

(4Z)-6-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl]-5-oxocyclopentyl]hex-4-enoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7Z)-9-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine

(4Z,7Z)-9-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-5-oxocyclopentyl]nona-4,7-dienoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7Z,10Z)-12-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine

(4Z,7Z,10Z)-12-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxypent-1-en-1-yl]-5-oxocyclopentyl]dodeca-4,7,10-trienoylcarnitine

C29H45NO7 (519.3196)


   

(4S,5E)-4-Hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine

(4S,5E)-4-Hydroxy-6-[(1S,2R,5S)-5-hydroxy-3-oxo-2-[(2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl]cyclopentyl]hex-5-enoylcarnitine

C29H45NO7 (519.3196)


   

(4Z,7S,8E)-7-Hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine

(4Z,7S,8E)-7-Hydroxy-9-[(1S,2R,5S)-5-hydroxy-2-[(2Z,5Z)-octa-2,5-dien-1-yl]-3-oxocyclopentyl]nona-4,8-dienoylcarnitine

C29H45NO7 (519.3196)


   

4-(dimethylamino)-N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

4-(dimethylamino)-N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

C27H45N5O5 (519.3421)


   

4-(dimethylamino)-N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

4-(dimethylamino)-N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

C27H45N5O5 (519.3421)


   

4-(dimethylamino)-N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

4-(dimethylamino)-N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide

C27H45N5O5 (519.3421)


   

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   
   

HexCer 18:0;2O/3:0

HexCer 18:0;2O/3:0

C27H53NO8 (519.3771)


   

HexCer 16:0;2O/5:0

HexCer 16:0;2O/5:0

C27H53NO8 (519.3771)


   

HexCer 12:0;2O/9:0

HexCer 12:0;2O/9:0

C27H53NO8 (519.3771)


   

HexCer 19:0;2O/2:0

HexCer 19:0;2O/2:0

C27H53NO8 (519.3771)


   

HexCer 9:0;2O/12:0

HexCer 9:0;2O/12:0

C27H53NO8 (519.3771)


   

HexCer 8:0;2O/13:0

HexCer 8:0;2O/13:0

C27H53NO8 (519.3771)


   

HexCer 13:0;2O/8:0

HexCer 13:0;2O/8:0

C27H53NO8 (519.3771)


   

HexCer 15:0;2O/6:0

HexCer 15:0;2O/6:0

C27H53NO8 (519.3771)


   

HexCer 14:0;2O/7:0

HexCer 14:0;2O/7:0

C27H53NO8 (519.3771)


   

HexCer 17:0;2O/4:0

HexCer 17:0;2O/4:0

C27H53NO8 (519.3771)


   

NAGly 11:0/18:3

NAGly 11:0/18:3

C31H53NO5 (519.3924)


   

NAGly 16:3/13:0

NAGly 16:3/13:0

C31H53NO5 (519.3924)


   

NAGly 18:3/11:0

NAGly 18:3/11:0

C31H53NO5 (519.3924)


   

NAGly 13:1/16:2

NAGly 13:1/16:2

C31H53NO5 (519.3924)


   

NAGly 13:0/16:3

NAGly 13:0/16:3

C31H53NO5 (519.3924)


   

NAGly 16:2/13:1

NAGly 16:2/13:1

C31H53NO5 (519.3924)


   

[2-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C27H54NO6P (519.3689)


   

2-aminoethyl [3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-hydroxypropyl] hydrogen phosphate

2-aminoethyl [3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-hydroxypropyl] hydrogen phosphate

C27H54NO6P (519.3689)


   

HexCer 11:0;2O/10:0

HexCer 11:0;2O/10:0

C27H53NO8 (519.3771)


   

HexCer 10:0;2O/11:0

HexCer 10:0;2O/11:0

C27H53NO8 (519.3771)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (11Z,14Z)-henicosa-11,14-dienoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (11Z,14Z)-henicosa-11,14-dienoate

C26H50NO7P (519.3325)


   

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tetradec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tetradec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]tridecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]tridecane-1-sulfonic acid

C27H53NO6S (519.3593)


   

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]dodecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]dodecane-1-sulfonic acid

C27H53NO6S (519.3593)


   

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)dodec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)pentadec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)pentadec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]undecane-1-sulfonic acid

C27H53NO6S (519.3593)


   

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)tridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)tridec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]pentadecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]pentadecane-1-sulfonic acid

C27H53NO6S (519.3593)


   

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tetradecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tetradecane-1-sulfonic acid

C27H53NO6S (519.3593)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] acetate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] acetate

C26H50NO7P (519.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] butanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] butanoate

C26H50NO7P (519.3325)


   

(E)-3-hydroxy-2-(2-hydroxyheptadecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxyheptadecanoylamino)dec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)undec-4-ene-1-sulfonic acid

C27H53NO6S (519.3593)


   

2-(Hexadecanoylamino)-3-hydroxydodecane-1-sulfonic acid

2-(Hexadecanoylamino)-3-hydroxydodecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

3-Hydroxy-2-(undecanoylamino)heptadecane-1-sulfonic acid

3-Hydroxy-2-(undecanoylamino)heptadecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

3-Hydroxy-2-(octadecanoylamino)decane-1-sulfonic acid

3-Hydroxy-2-(octadecanoylamino)decane-1-sulfonic acid

C28H57NO5S (519.3957)


   

3-Hydroxy-2-(tetradecanoylamino)tetradecane-1-sulfonic acid

3-Hydroxy-2-(tetradecanoylamino)tetradecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

3-Hydroxy-2-(pentadecanoylamino)tridecane-1-sulfonic acid

3-Hydroxy-2-(pentadecanoylamino)tridecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

2-(Decanoylamino)-3-hydroxyoctadecane-1-sulfonic acid

2-(Decanoylamino)-3-hydroxyoctadecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

2-(Heptadecanoylamino)-3-hydroxyundecane-1-sulfonic acid

2-(Heptadecanoylamino)-3-hydroxyundecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

3-Hydroxy-2-(tridecanoylamino)pentadecane-1-sulfonic acid

3-Hydroxy-2-(tridecanoylamino)pentadecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

2-(Dodecanoylamino)-3-hydroxyhexadecane-1-sulfonic acid

2-(Dodecanoylamino)-3-hydroxyhexadecane-1-sulfonic acid

C28H57NO5S (519.3957)


   

[2-acetyloxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-acetyloxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

N-(decanoyl)-4E-heptadecasphingenine-1-phosphate

N-(decanoyl)-4E-heptadecasphingenine-1-phosphate

C27H54NO6P (519.3689)


   

N-(dodecanoyl)-4E-pentadecasphingenine-1-phosphate

N-(dodecanoyl)-4E-pentadecasphingenine-1-phosphate

C27H54NO6P (519.3689)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] pentanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] pentanoate

C26H50NO7P (519.3325)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] propanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] propanoate

C26H50NO7P (519.3325)


   

[2-hydroxy-3-[(9E,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(9E,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

[(2R)-3-hydroxy-2-[(9Z,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-3-hydroxy-2-[(9Z,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

lysoDGTS 20:5

lysoDGTS 20:5

C30H49NO6 (519.356)


   

[(2R)-2-hydroxy-3-[(9E,11E)-octadeca-9,11-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-hydroxy-3-[(9E,11E)-octadeca-9,11-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

[(2R)-2-hydroxy-3-[(9E,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-hydroxy-3-[(9E,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

[(2R)-2-hydroxy-3-[(6E,9E)-octadeca-6,9-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-hydroxy-3-[(6E,9E)-octadeca-6,9-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO7P (519.3325)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(nonanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(nonanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[[(4E,8E)-2-acetamido-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-acetamido-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C26H52N2O6P+ (519.3563)


   

1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


A lysophosphatidylcholine 18:2 in which the acyl group at position 1 is (9Z,12Z)-octadecadienoyl.

   

2-linoleoyl-sn-glycero-3-phosphocholine

2-linoleoyl-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


A lysophosphatidylcholine 18:2 in which the acyl group is specified as linoleoyl and is located at position 2.

   

1-(2E,4E-octadecadienoyl)-sn-glycero-3-phosphocholine

1-(2E,4E-octadecadienoyl)-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


   

1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphocholine

1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphocholine

C27H54NO6P (519.3689)


   

linoleoyl-sn-glycero-3-phosphocholine

linoleoyl-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


A lysophosphatidylcholine in which the acyl group (position not specified) is linoleoyl.

   

lysophosphatidylcholine(0:0/18:2)

lysophosphatidylcholine(0:0/18:2)

C26H50NO7P (519.3325)


A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 18 carbons and 2 double bonds.

   

Lysophosphatidylcholine(18:2/0:0)

Lysophosphatidylcholine(18:2/0:0)

C26H50NO7P (519.3325)


A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 18 carbons and 2 double bonds.

   

lysophosphatidylcholine (18:2/0:0)

lysophosphatidylcholine (18:2/0:0)

C26H50NO7P (519.3325)


A lysophosphatidylcholine 18:2 in which the acyl group is located at position 1.

   

Lysophosphatidylcholine 18:2

Lysophosphatidylcholine 18:2

C26H50NO7P (519.3325)


A lysophosphatidylcholine in which the acyl group (position not specified) contains 18 carbons and 2 double bonds.

   

1-Linoleoyl-sn-glycero-3-phosphocholine

1-Linoleoyl-sn-glycero-3-phosphocholine

C26H50NO7P (519.3325)


A lysophosphatidylcholine 18:2 in which the acyl group at position 1 is (9Z,12Z)-octadecadienoyl.

   

PE(21:2)

PE(10:0(1)_11:2)

C26H50NO7P (519.3325)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

PC(18:2)

PC(8:0(1)_10:2)

C26H50NO7P (519.3325)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   

LPC 18:2(9Z,12Z)

LPC 18:2(9Z,12Z)

C26H50NO7P (519.3325)


   
   
   
   
   
   

PC P-14:0/4:1 or PC O-14:1/4:1

PC P-14:0/4:1 or PC O-14:1/4:1

C26H50NO7P (519.3325)


   
   

PC P-16:1/2:0 or PC O-16:2/2:0

PC P-16:1/2:0 or PC O-16:2/2:0

C26H50NO7P (519.3325)


   
   

PC P-18:1 or PC O-18:2

PC P-18:1 or PC O-18:2

C26H50NO7P (519.3325)


   
   
   

LPE P-22:1 or LPE O-22:2

LPE P-22:1 or LPE O-22:2

C27H54NO6P (519.3689)


   

CerP 14:1;O2/13:0

CerP 14:1;O2/13:0

C27H54NO6P (519.3689)


   

CerP 14:2;O2/12:0;O

CerP 14:2;O2/12:0;O

C26H50NO7P (519.3325)


   

CerP 15:1;O2/12:0

CerP 15:1;O2/12:0

C27H54NO6P (519.3689)


   

CerP 15:2;O2/11:0;O

CerP 15:2;O2/11:0;O

C26H50NO7P (519.3325)


   

CerP 16:1;O2/11:0

CerP 16:1;O2/11:0

C27H54NO6P (519.3689)


   

CerP 16:2;O2/10:0;O

CerP 16:2;O2/10:0;O

C26H50NO7P (519.3325)


   

CerP 17:1;O2/10:0

CerP 17:1;O2/10:0

C27H54NO6P (519.3689)


   
   
   

ST 27:3;O5;Gly

ST 27:3;O5;Gly

C29H45NO7 (519.3196)


   

ST 28:2;O4;Gly

ST 28:2;O4;Gly

C30H49NO6 (519.356)


   

ST 29:1;O3;Gly

ST 29:1;O3;Gly

C31H53NO5 (519.3924)


   

ST 21:2;O2;HexNAc

ST 21:2;O2;HexNAc

C29H45NO7 (519.3196)


   

ST 22:1;O;HexNAc

ST 22:1;O;HexNAc

C30H49NO6 (519.356)


   

(1s,12s,15s,20r)-7-[(s)-(3,3-dimethyloxiran-2-yl)(hydroxy)methyl]-15-hydroxy-1,16,16,20-tetramethyl-8-(3-methylbut-2-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-one

(1s,12s,15s,20r)-7-[(s)-(3,3-dimethyloxiran-2-yl)(hydroxy)methyl]-15-hydroxy-1,16,16,20-tetramethyl-8-(3-methylbut-2-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-one

C33H45NO4 (519.3348)


   

(2-{[(2r)-2-hydroxy-3-[(9z,12z)-octadeca-9,12-dienoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-[(9z,12z)-octadeca-9,12-dienoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium

C26H50NO7P (519.3325)